The FDA halted the study for JCAR015 last week following the death of three patients who died after a chemotherapy agent called fludarabine was added to the trial.
The FDA is allowing Juno to continue the trial under a new protocol that does not include fludarabine.
JCAR015 is an experimental T cell therapy that involves extracting a patient’s immune system T cells, altering their DNA to improve their ability to detect and kill cancer cells, and then infuse them back into the patient.
Shares of the Seattle-based drug company jumped 28 percent after the FDA lifted the clinical hold.
More articles on infection control and clinical quality:
Alzheimer’s vaccine could be available soon
Northwell Health wins patient safety awards from the NY hospital association
Patients with more say in treatment have fewer side effects
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
